The DOI matches its Crossref record.
High efficacy treatment of murine Pseudomonas aeruginosa catheter-associated urinary tract infections using the c-di-GMP modulating anti-biofilm compound Disperazol in combination with ciprofloxacin
Abstract
Persistent urinary tract infections (UTIs) in hospitalized patients constitute an important medical problem. It is estimated that 75% of nosocomial UTIs are associated with urinary tract catheters with P. aeruginosa being a species that forms biofilms on these catheters. These infections are highly resistant to standard-of-care antibiotics, and the effects of the host immune defenses, which allows for development of persistent infections. With antibiotics losing their efficacy, new treatment options against resilient infections, such as catheter-associated urinary tract infections (CAUTIs), are critically needed. Central to our anti-biofilm approach is the manipulation of the c-di-GMP signaling pathway in P. aeruginosa to switch bacteria from the protective biofilm to the unprotected planktonic mode of life. We recently identified a compound (H6-335-P1), that stimulates the c-di-GMP degrading activity of the P. aeruginosa BifA protein which plummets the intracellular c-di-GMP content and induces dispersal of P. aeruginosa biofilm bacteria into the planktonic state. In the present study, we formulated H6-335-P1 as a hydrochloride salt (Disperazol), which is water-soluble and facilitates delivery via injection or oral administration. Disperazol can work as a monotherapy, but we observed a 100-fold improvement in efficacy when treating murine P. aeruginosa CAUTIs with a Disperazol/ciprofloxacin combination. Biologically active Disperazol reached the bladder 30 min after oral administration. Our study provides proof of concept that Disperazol can be used in combination with a relevant antibiotic for effective treatment of CAUTIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An analog, H6-335-P1, activated the BifA PDE and, when combined with antibiotics, cleared implant-associated infections in mice [188,189].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [189]
In the citing paper
“In P. aeruginosa, it reduced c-di-GMP, prevented biofilm formation, and dispersed established biofilms.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [189]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 37
- 10.1016/S0140-6736(21)02724-0 · DOI · Paper page
- 10.3389/fmicb.2019.00913 · DOI · Paper page
- 10.1093/femsre/fux010 · DOI · Paper page
- 10.1099/mic.0.27463-0 · DOI · Paper page
- 10.1126/science.284.5418.1318 · DOI · Paper page
- 10.1099/mic.0.2006/003863-0 · DOI · Paper page
- 10.3389/fimmu.2021.625597 · DOI · Paper page
- 10.1371/journal.ppat.1000213 · DOI · Paper page
- 10.1002/bit.21838 · DOI · Paper page
- 10.1093/cid/ciab696 · DOI
- 10.1073/pnas.0507170102 · DOI · Paper page
- 10.1111/1462-2920.12448 · DOI · Paper page
- 10.1111/j.1574-6968.2006.00493.x · DOI
- 10.1128/JB.00119-09 · DOI · Paper page
- 10.1038/nrmicro.2016.190 · DOI · Paper page
- 10.1128/JB.186.21.7312-7326.2004 · DOI · Paper page
- 10.1128/JB.00779-06 · DOI · Paper page
- 10.1128/JB.187.14.4774-4781.2005 · DOI · Paper page
- 10.1073/pnas.0600345103 · DOI · Paper page
- 10.1111/j.1462-2920.2008.01842.x · DOI
- 10.1038/nrmicro2109 · DOI · Paper page
- 10.1128/IAI.00332-13 · DOI
- 10.1128/AAC.02431-20 · DOI
- 10.1038/s41522-021-00225-4 · DOI · Paper page
- 10.1039/d1md00275a · doi:10.1039/d1md00275a
- 10.1038/s41564-023-01403-0 · DOI
- 10.5402/2012/195727 · DOI · Paper page
- 10.3390/molecules23071719 · DOI · Paper page
- 10.1128/AEM.00414-12 · DOI · Paper page
- 10.1016/j.cmi.2014.10.024 · DOI · Paper page
- 10.1038/s41579-022-00682-4 · DOI · Paper page
- 10.1128/JB.01515-06 · DOI · Paper page
- 10.1038/35023079 · DOI · Paper page
- 10.1128/JB.183.18.5213-5222.2001 · DOI · Paper page
- 10.1099/mic.0.000354 · DOI
- 10.3791/52892 · DOI
- 10.1093/jac/dks002 · DOI · Paper page
Cited by
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Metadata
- Authors
- Hultqvist, L. D., Andersen, J. B., Nilsson, C. M., Jansen, C. U., Rybtke, M., Jakobsen, T. H., Nielsen, T. E., Qvortrup, K., Moser, C., Graz, M., Qvortrup, K., Tolker-Nielsen, T., & Givskov, M.
- Affiliations
- Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Chemistry, Technical University of Denmark, Lyngby, Denmark
- Department of Biomedical Sciences, CFIM, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2024-05-08
- ISSN
- 0066-4804
- 1098-6596
- Cited by
- 13
- References
- 0
- Language
- en
- Licence
- doi.org/10.1128/ASMCopyrightv2 (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Funders
- Sygeforsikringen Danmark (2021-0300)
- Novo Nordisk Fonden (NNF18SA0034966)
- The Danish Innovation Foundation (0161-00003)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High efficacy treatment of murine Pseudomonas aeruginosa catheter-associated urinary tract infections using the c-di-GMP modulating anti-biofilm compound Disperazol in combination with ciprofloxacin. https://app.cochat.ai/papers/10.1128/aac.01481-23
- The paper
- Hultqvist, L. D., Andersen, J. B., Nilsson, C. M., Jansen, C. U., Rybtke, M., Jakobsen, T. H., Nielsen, T. E., Qvortrup, K., Moser, C., Graz, M., Qvortrup, K., Tolker-Nielsen, T., & Givskov, M. (2024). High efficacy treatment of murine Pseudomonas aeruginosa catheter-associated urinary tract infections using the c-di-GMP modulating anti-biofilm compound Disperazol in combination with ciprofloxacin. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01481-23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.